Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for resectable locally advanced HNSCC
ChiCTR2500113576Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab, paclitaxel and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Pathological complete response rate (pCR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxelcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500113576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113576.